This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Egan, J. B. Articles by Thompson, P. A. Search for Related Content PubMed PubMed Citation Articles by Egan, J. B. Articles by Thompson, P. A.

Presence of a TA Haplotype in the APC Gene Containing the Common 1822 Polymorphism and Colorectal Adenoma

¹ Arizona Cancer Center, ² Mel and Enid Zuckerman Arizona College of Public Health, and Departments of ³ Cell Biology and Anatomy and ⁴ Pathology, University of Arizona, Tucson, Arizona; ⁵ Department of Integrated Natural Sciences, Arizona State University, Glendale, Arizona; and ⁶ Department of Basic Medical Sciences, University of Arizona College of Medicine-Phoenix, in partnership with Arizona State University, Phoenix, Arizona

Requests for reprints: Patricia A. Thompson, Arizona Cancer Center, University of Arizona, P.O. Box 245024, Tucson, AZ 85724-5024. Phone: 520-626-3138; Fax: 520-626-5348; E-mail: pthompson{at}azcc.arizona.edu.

Key Words: APC • Wnt signaling • colorectal adenoma • haplotype

Acquired or inherited mutations in the adenomatous polyposis coli (APC) tumor suppressor gene are causally linked to colorectal cancer. Given the significance of APC in colorectal cancer, we investigated the association between common single-nucleotide polymorphisms (SNP) in the APC gene and the odds of developing metachronous colorectal adenomas as a surrogate measure of colorectal cancer risk. Coding SNPs at codons 486, 1678, 1822, 1960, and 2502 were analyzed in a total of 1,399 subjects who participated in two randomized clinical trials for the prevention of colorectal adenomas. No association was found for any single SNP and the odds of metachronous adenoma. In contrast, a TA haplotype (codons 486 and 1822) was associated with a statistically significant 27% and 26% reduction in the odds of any and nonadvanced metachronous adenoma after adjustment for baseline adenoma characteristics [odds ratio (OR), 0.73; 95% confidence interval (95% CI), 0.59–0.91 and OR, 0.74; 95% CI, 0.57–0.94], respectively. No significant reduction in odds was observed for advanced metachronous lesions. Diplotype analysis revealed a strong gene dose effect with carriers of two alleles containing TT-AA (codons 486 and 1822, respectively) having an 89% lower odds for advanced metachronous adenomas (OR, 0.11; 95% CI, 0.01–0.80) when compared with the common CC-AA diplotype (codons 486 and 1822, respectively). Our findings support an important role for germ-line allele sequence in the APC gene and individual risk of metachronous adenomatous polyps. [Cancer Res 2008;68(14):6006–13]